Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Mitterberger

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
BJU International|January 15, 2008
Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mLAlexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
European Urology|July 1, 2008
Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination projectMargot Wink, Ferdinand Frauscher, David Cosgrove, et al.
European Urology|November 27, 2007
Comparison of contrast-enhanced color Doppler imaging (CDI), computed tomography (CT), and magnetic resonance imaging (MRI) for the detection of crossing vessels in patients with ureteropelvic junction obstruction (UPJO)Michael Mitterberger, Germar M Pinggera, Richard Neururer, et al.
BJU International|October 19, 2007
Multimodal evaluation of renal perfusional changes due to extracorporeal shock wave lithotripsyMichael Mitterberger, Germar M Pinggera, Richard Neururer, et al.
BJU International|October 10, 2007
Comparison of the precision of transurethral endoscopic versus ultrasound-guided application of injectablesMichael Mitterberger, Germar M Pinggera, Alexandre Pelzer, et al.
BJU International|February 12, 2008
Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?Alexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
BJU International|March 18, 2008
Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference?Alexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
BJU International|January 22, 2008
Real-time virtual ultrasonographic radiofrequency ablation of renal cell carcinomaOsamu Ukimura, Michael Mitterberger, Koji Okihara, et al.
World Journal of Urology|May 23, 2019
En bloc re-resection of high-risk NMIBC after en bloc resection: results of a multicenter observational studyRodolfo Hurle, Paolo Casale, Massimo Lazzeri, et al.
Clinical Genitourinary Cancer|June 26, 2019
Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS StudyManuela Schmidinger, Renate Pichler, Wolfgang Loidl, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
BJU International|January 15, 2008
Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mLAlexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
European Urology|July 1, 2008
Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination projectMargot Wink, Ferdinand Frauscher, David Cosgrove, et al.
European Urology|November 27, 2007
Comparison of contrast-enhanced color Doppler imaging (CDI), computed tomography (CT), and magnetic resonance imaging (MRI) for the detection of crossing vessels in patients with ureteropelvic junction obstruction (UPJO)Michael Mitterberger, Germar M Pinggera, Richard Neururer, et al.
BJU International|October 19, 2007
Multimodal evaluation of renal perfusional changes due to extracorporeal shock wave lithotripsyMichael Mitterberger, Germar M Pinggera, Richard Neururer, et al.
BJU International|October 10, 2007
Comparison of the precision of transurethral endoscopic versus ultrasound-guided application of injectablesMichael Mitterberger, Germar M Pinggera, Alexandre Pelzer, et al.
BJU International|February 12, 2008
Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?Alexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
BJU International|March 18, 2008
Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference?Alexandre E Pelzer, Daniela Colleselli, Jasmin Bektic, et al.
BJU International|January 22, 2008
Real-time virtual ultrasonographic radiofrequency ablation of renal cell carcinomaOsamu Ukimura, Michael Mitterberger, Koji Okihara, et al.
World Journal of Urology|May 23, 2019
En bloc re-resection of high-risk NMIBC after en bloc resection: results of a multicenter observational studyRodolfo Hurle, Paolo Casale, Massimo Lazzeri, et al.
Clinical Genitourinary Cancer|June 26, 2019
Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS StudyManuela Schmidinger, Renate Pichler, Wolfgang Loidl, et al.
Pageof 7